

Title **Concomitant Use of Antiplatelet Therapy with Edoxaban or Warfarin in Patients with Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial**

Presenter (Oral) **Haiyan Xu, MD, PhD**

Session Treatment of Arrhythmias: Pharmacologic: Novel Anticoagulants

Time 3:45 – 3:55 PM

Location S401bcd

Title **Efficacy and Safety of Edoxaban for the Management of Elderly Patients with Atrial Fibrillation: ENGAGE AF-TIMI 48**

Presenter (Oral) **Eri Toda Kato, MD, PhD**

Session Treatment of Arrhythmias: Pharmacologic: Novel Anticoagulants

Time 4:00 – 4:10 PM

Location S401bcd

WEDNESDAY, NOVEMBER 19TH

Title **Heart Failure Signals with Diabetes Drugs: PPAR-Gamma, PPAR-Alpha/Gamma, and DPP 4 Inhibitors**

Presenter (Oral) **Benjamin M. Scirica, MD, MPH**

Session Failure Is Not an Option: The Intersection of Diabetes and Heart Failure Epidemics

Time 9:45 – 10:00 AM

Location S100ab

Title **Efficacy and Safety of Edoxaban Compared with Warfarin in Patients With Atrial Fibrillation and Heart Failure: Insights From ENGAGE AF-TIMI 48**

Presenter (Poster) **Giulia Magnani, MD**

Session Heart Failure: Outcomes and Clinical Trials

Time 9:30 – 11:00 AM

Location South Hall A2, Core 5, Poster 12680

About the TIMI Study Group

Since its inception in 1984, the principal goal of the TIMI Study Group has been to conduct high quality clinical trials that enhance the care of patients suffering from cardiovascular disease and its risk factors. TIMI has led a wide array of phase 1 to phase 4 trials, as well as registries. These have ranged in size from less than 30 to more than 25,000 subjects. The interventions studied include fibrinolytic, antithrombotic, anti-platelet, anti-ischemic, lipid lowering, anti-inflammatory, and anti-diabetic agents as well as percutaneous coronary intervention. In addition, the TIMI Study Group has used its growing database of more than 300,000 subjects and their clinical findings, electrocardiograms, angiograms, biomarkers, and genotypes to enhance the understanding of cardiovascular disease and its risk factors. An important corollary goal has been to train the next generation of clinical investigators. TIMI is especially proud of these trainees who have assumed leadership positions in leading institutions around the world.



2014 INVESTIGATOR PRESENTATION SCHEDULE

NOVEMBER 16 – 19

TIMI Study Group

350 Longwood Avenue
Office Level One
Boston, Massachusetts 02115
617.278.0145 or
1.800.385.4444
TIMI@partners.org
www.timi.org
twitter: @TIMIstudygroup

SUNDAY, NOVEMBER 16TH

Title **Growth Differentiation Factor-15 Independently Predicts 2 Year Mortality in Patients with Acute Coronary Syndrome: Observations from the A to Z Trial**

Presenter (Poster) **Ethan C. Kosova, MD**

Session Risk Modifiers in Cardiovascular Disease

Time 9:30 – 11:00 AM

Location South Hall A2, Core 7, Poster 16378

Title **Prevalence, Characteristics, Treatment and In-hospital Outcomes of Diabetes Mellitus in Patients with Acute Myocardial Infarction in China from the China Acute Myocardial Infarction Registry**

Presenter (Poster) **Haiyan Xu, MD, PhD**

Session Risk Factors for Cardiovascular Events

Time 9:30 – 11:00 AM

Location South Hall A2, Core 7, Poster 19423

Title **Presidential Address: Saving and Improving Lives in the Information Age**

Presenter **Elliot Antman, MD**

Session Opening Session

Time 1:00 – 3:00 PM

Location North Hall B

MONDAY, NOVEMBER 17TH

Title **IMPROVE-IT Trial: A comparison of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Cardiovascular Outcomes after Acute Coronary Syndromes**

Presenter **Christopher P. Cannon, MD**

Session Late Breaking Trials: Anti-Lipid Therapy and Prevention of CAD

Time 10:45 AM – 12:13 PM

Location North Hall B

Title **Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Death in Patients after an Acute Coronary Syndrome**

Presenter (Poster) **Michelle L. O'Donoghue, MD, MPH**

Session Insights into the Treatment and Outcomes of Patients with Acute Coronary Syndromes

Time 3:00 – 4:30 PM

Location South Hall A2, Core 7, Poster 17332

Title **Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Economic Study**

Presenter (Poster) **Elizabeth A. Magnuson, ScD**

Session Anticoagulants for Atrial Fibrillation and Venous Thromboembolic Disease

Time 3:00 – 4:30 PM

Location South Hall A2, Core 7, Poster #17332

TUESDAY, NOVEMBER 18TH

Title **Pharmacogenetics Versus Other Biomarkers to Guide Clopidogrel Therapy**

Presenter (Oral) **Jessica L. Mega, MD, MPH**

Session Challenges and Opportunities in Personalized Medicine

Time 7:30 – 7:45 AM

Location S104

Title **Secondary Observations from SAVOR-TIMI 53 Trial of Saxagliptin**

Presenter (Oral) **Benjamin M. Scirica, MD, MPH**

Session Updates of Cardiovascular Outcomes Trials of Drugs for Diabetes

Time 7:45 – 8:00 AM

Location S501

Title **Cardiovascular Biomarkers and Long-Term Outcomes in Patients with Type 2 Diabetes Mellitus Treated with Alogliptin vs. Placebo in the EXAMINE Trial**

Presenter (Poster) **David A. Morrow**

Session Diabetes Mellitus and CVD: Prevention and Management IV

Time 9:30 – 11:00 AM

Location South Hall A2, Core 2, Poster 17295

Title **IMPROVE-IT Trial: A Comparison of Ezetimibe/Simvastatin vs. Simvastatin Monotherapy on Cardiovascular Outcomes after Acute Coronary Syndromes**

Presenter **Christopher P. Cannon, MD**

Session Meet The Trialists

Time 1:00 – 1:45 PM

Location Science & Technology Hall, Booth 870

Title **Impact of Baseline PCSK9 Levels on the Efficacy of Evolocumab, a Monoclonal Antibody Against PCSK9**

Presenter (Poster) **Nihar Desai, MD, MPH**

Session Lipids, Lipoprotein Metabolism and Biomarkers

Time 3:00 – 4:30 PM

Location South Hall A2, Core 2, Poster 16196

Title **Safety and Tolerability of Very Low LDL-C Levels in Patients Treated with 52 Weeks of Evolocumab (AMG 145)**

Presenter (Poster) **Michael J. Koren, MD**

Session Lipids, Lipoprotein Metabolism and Biomarkers

Time 3:00 – 4:30 PM

Location South Hall A2, Core 2, Poster 16865

Title **Multimarker Risk Stratification in Patients with Acute Myocardial Infarction**

Presenter (Poster) **Michelle L. O'Donoghue, MD, MPH**

Session New Developments in Acute Coronary Syndromes

Time 3:00 – 4:30 PM

Location South Hall A2 – Core 7, Poster 17350

Title **Systemic, Non-cerebral, Arterial Embolism in 21,105 Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Results from the ENGAGE AF-TIMI 48 Trial**

Presenter (Poster) **Bram J. Geller, MD**

Session Treatment of Arrhythmias: Pharmacologic – Stroke and Bleeding in AF

Time 3:00–4:30 PM

Location South Hall A2, Core 4, Poster 18597

Title **Outcomes in Stable Patients with Prior Atherothrombosis Receiving Vorapaxar who Present with a New Acute Coronary Syndrome: Insights from the TRA 2°P-TIMI 50 Trial**

Presenter (Oral) **Marc P. Bonaca, MD, MPH**

Session Medical Therapy in Chronic Ischemic Heart Disease

Time 3:45 – 3:55 PM

Location S103bc